Retesting Tesamorelin: following up on last cycle's discrepancies
1 independently tested samples across 1 companies, and what the results say about Tesamorelin.
Dr. Alan Mercer··11 min read
Tesamorelin is a ghrh analog with a development status of "fda-approved (branded form)". The Institute rates the strength of its published evidence as strong. A stabilized GHRH analog approved for HIV-associated lipodystrophy, with visceral-fat reduction demonstrated in phase 3 trials.
This report covers the Tesamorelin samples processed in our most recent testing cycle. Every specimen was purchased anonymously at retail, transferred under chain-of-custody documentation, and analysed by an independent contract laboratory.
The Institute has independently tested 1 Tesamorelin sample from 1 company. 0% met their label claims on purity and content. Measured purity ranged from 57.8% to 57.8%, averaging 57.8%. 1 sample failed verification outright. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
23 samples, 12 sellers, one compound with almost no human evidence behind it. Measured purity ranged from 61% to 98.9%.
Institute Investigation
Free download
Get the free Peptide Playbook, plus new breakthroughs as they happen.
What peptides are, why people are using them, and what results people are talking about,
in plain English. Sign up and we email you the Playbook right away.
